Social and Health Economics and Outcomes Group (SHEOG) @LinkedIn https://www.linkedin.com/groups/8678341 You are welcome to join SHEOG! SHEOG @LinkedIn aims to encourage discussion about economic evaluation
Virtual Hospital 2.0 mid-assessment and Isaacus pre-production project results are presented as podiums in an international eHealth2018 congress ESiOR takes part in the international eHealth
ESiOR Oy gets stronger… We welcome the 10th member of our team! Namely, ISPOR-awarded Saara Huoponen has joined our team as health economic consultant and
Conditional reimbursement context: An economic evaluation including a risk-sharing scheme A hybrid-modeling study that evaluated the clinical outcomes, cost-effectiveness, and budget impact of biologic rheumatoid
Well-known Market Access professionals, Satu Rauhala and Akseli Kivioja, joined ESiOR on August 7th, 2017. Their joint experience is unique: Finnish Pharmaceuticals Pricing Board, pharma industry,
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a
Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland ESiOR studied relapsing-remitting MS (RRMS) progression and
Janne Martikainen, PhD (health economics), Adjunct Professor (economic evaluation of pharmaceuticals) in Turku University and one of ESiOR’s health economists and partners is now also
Development of business and services portfolio Project’s goals are to innovate and develop new business, support business growth and strengthen national and international competitiveness of
ESiOR Ltd takes part in Nordic conference on Real World Data – Collaboration between pharma industry and Academia on November 29-30, 2016, in Helsinki. We
Many patients with major depressive disorder (MDD) do not have adequate response to the first medical treatment or have adverse effects that lead to treatment
A large proportion of patients with atrial fibrillation (AF) do not attain the treatment targets with traditional warfarin treatment. As a result, they remain at
